AI Proteins
Designs miniproteins from scratch with AI, then makes and tests them in a high-throughput lab, as drugs that are smaller than antibodies; its own pipeline starts in oncology.
Money and evidence
Latest round, Series A, 2025-11-20: the record then held no research entry for the company. The first research entry is dated 2026-08-05; the highest level so far is 4 (Tested in the physical world).
Rounds and research, on one timeline
- 2026-08-05Research
Level 4 · Tested in the physical world
AI Proteins publishes the lab workflow that turns DNA into purified protein in three days, and made 87 of 96 test proteins with it
AI can now propose far more protein designs than labs can make and measure, so the bottleneck has moved to production. A company whose business is designing miniproteins has published the part of its pipeline that makes them, with the plasmids at Addgene and the robot scripts on GitHub, so other labs can make and test designs at the same pace and add to shared training data.
- 2025-11-20Series ARound
$41.5M
For: speed up AI-driven design and development of de novo miniprotein medicines
Models and platform
Business Wire release, read through BioSpace's copy. It names the two existing investors and 'others'; no valuation. The same day the company adopted a hub-and-spoke model, spinning programs out as LLC subsidiaries.
Co-lead · Mission BioCapitalCo-lead · Santé VenturesExisting investor · Lightchain CapitalExisting investor · Cobro Ventures
On the deal: Omar Khalil (Managing Director; spoke for the firm in the announcement, Santé Ventures); Steve Tregay (Managing General Partner; spoke for the firm in the announcement, Mission BioCapital)
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.